Skip to main content
Fig. 8 | Alzheimer's Research & Therapy

Fig. 8

From: Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

Fig. 8

Impact of selective serotonin reuptake inhibitor (SSRI) medication. Boxplots highlighting differences between study participants from the AD study group who had been prescribed SSRI medication and those who had not. There were no significant differences (analysis by Mann-Whitney U tests) when comparing the metabolites tryptophan and the downstream metabolite 5-hydroxyindoleaceitic acid in both urine and serum. There was also no significant difference in serotonin in urine; however, in serum, there were significantly lower levels of serotonin in the AD group who were prescribed SSRI medication for depression. Further longitudinal work would be required to determine if this is a result of the SSRI medication or due to the underlying pathophysiology of the individual that leads to treatment for depressive symptoms

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193